

## TAILORx exploratory subgroup analysis reinforces evidence that the Recurrence Score<sup>®</sup> result predicts with precision which patients are more likely to benefit from chemotherapy

Total Patients N=9719	RS 0-15	RS 16-20	RS 21-25	RS 26-100
Age $\leq 50$ years n=3054 (31.4%)	No CT Benefit n=1230	<b>1.6% CT Benefit<sup>1</sup></b> n=923	<b>6.5% CT Benefit<sup>1</sup></b> n=492	<b>CT Benefit<sup>1</sup></b> n=409
<b>Low clinical risk*</b> <ul style="list-style-type: none"> <li>Tumor Size <math>\leq 3</math> cm and Grade 1</li> <li>Tumor Size <math>\leq 2</math> cm and Grade 2</li> <li>Tumor Size <math>\leq 1</math> cm and Grade 3</li> </ul>		No CT benefit n=671*	<b>~6.4% CT benefit<sup>1</sup></b> n=319*	
<b>High clinical risk*</b> <ul style="list-style-type: none"> <li>All other cases with known values for grade and tumor size</li> </ul>		<b>~6.5% CT benefit<sup>1</sup></b> n=215*	<b>~8.7% CT benefit<sup>1</sup></b> n=157*	

\* Clinical risk data were not available for 3% of patients enrolled in TAILORx; n= the portion of enrolled patients with clinical risk parameters available. Clinical risk defined via Modified Adjuvant! Online

**References:** Sparano et al. N Engl J Med. 2018; Paik et al. J Clin Oncol. 2006; Sparano and Paik. J Clin Oncol. 2008; Sparano et al. N Engl J Med 2019.  
Oncotype DX Breast Recurrences Score, Oncotype DX, are trademarks of Genomic Health Inc, an Exact Sciences corporation.  
© 2020 Genomic Health Inc., an Exact Sciences corporation. All rights reserved. ESX11936\_0420

<sup>1</sup> Absolute chemotherapy benefit  
RS: Recurrence Score<sup>®</sup> result  
CT: Chemotherapy

## TAILORx results reinforce evidence that the Recurrence Score® result predicts with precision which patients are more likely to benefit from chemotherapy

Total Patients N=9719	RS 0-25	RS 26-100
Age >50 years n=6665 (68.6%)	No CT Benefit n=5685	<b>CT Benefit<sup>1</sup></b> <b>n=980</b>

**References:** Sparano et al. N Engl J Med. 2018; Paik et al. J Clin Oncol. 2006; Sparano and Paik. J Clin Oncol. 2008; Sparano et al. N Engl J Med 2019.  
Oncotype DX Breast Recurrences Score, Oncotype DX, are trademarks of Genomic Health Inc, an Exact Sciences corporation.  
© 2020 Genomic Health Inc., an Exact Sciences corporation. All rights reserved. ESX11936\_0420

<sup>1</sup>Absolute chemotherapy benefit  
RS: Recurrence Score® result  
CT: Chemotherapy